WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will ...

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team led by Professor Won Jong Kim from the Department of Chemistry at POSTECH, in collaboration with the Korea ...

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.

Alys Pharmaceuticals has received clearance from the US FDA and Health Canada for a Phase IIa trial of ALY-101 for alopaecia ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...